[HTML][HTML] Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
MC Walter, P Reilich, S Thiele, J Schessl… - Orphanet Journal of …, 2013 - Springer
MC Walter, P Reilich, S Thiele, J Schessl, H Schreiber, K Reiners, W Kress, C Müller-Reible…
Orphanet Journal of Rare Diseases, 2013•SpringerBackground Dysferlinopathies are autosomal recessive disorders caused by mutations in
the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide
range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and
limb girdle muscular dystrophy type 2B (LGMD2B). Methods We assessed the one-year-
natural course of dysferlinopathy, and the safety and efficacy of deflazacort treatment in a
double-blind, placebo-controlled cross-over trial. After one year of natural course without …
the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide
range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and
limb girdle muscular dystrophy type 2B (LGMD2B). Methods We assessed the one-year-
natural course of dysferlinopathy, and the safety and efficacy of deflazacort treatment in a
double-blind, placebo-controlled cross-over trial. After one year of natural course without …
Background
Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B).
Methods
We assessed the one-year-natural course of dysferlinopathy, and the safety and efficacy of deflazacort treatment in a double-blind, placebo-controlled cross-over trial. After one year of natural course without intervention, 25 patients with genetically defined dysferlinopathy were randomized to receive deflazacort and placebo for six months each (1 mg/kg/day in month one, 1 mg/kg every 2nd day during months two to six) in one of two treatment sequences.
Results
During one year of natural course, muscle strength declined about 2% as measured by CIDD (Clinical Investigation of Duchenne Dystrophy) score, and 76 Newton as measured by hand-held dynamometry. Deflazacort did not improve muscle strength. In contrast, there is a trend of worsening muscle strength under deflazacort treatment, which recovers after discontinuation of the study drug. During deflazacort treatment, patients showed a broad spectrum of steroid side effects.
Conclusion
Deflazacort is not an effective therapy for dysferlinopathies, and off-label use is not warranted. This is an important finding, since steroid treatment should not be administered in patients with dysferlinopathy, who may be often misdiagnosed as polymyositis.
Trial registration
This clinical trial was registered at http://www.ClincalTrials.gov , identifier: NCT00527228 , and was always freely accessible to the public.
Springer